MedTrace Logo

Development of Novel Therapies for NIDDM

NCT01905722 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-05-31

No results posted yet for this study

Summary

The overarching goal of this program project grant is the development of technologies that lead to new methods for studying, detecting, and treating type 2 diabetes, and their integration with hypothesis-driven diabetes research projects.

Project 4 of the grant, led by Dr. Craig Malloy at UTSW, will develop and apply new technology in MRI to test core hypotheses about the development of insulin resistance in people. The long-term goal is to develop technology to monitor metabolism in skeletal muscle, brain and the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in a 3 Tesla and 7 Tesla MRI scanners. These advanced imaging methods allow researchers to take pictures of the inside of the body and to measure metabolism as it occurs in the MRI scanner. Standard clinical MRI for medical diagnosis and treatment is performed in a 1 Tesla or 3 Tesla MRI scanner.

A primary goal of the 7 Tesla research program is to develop a group of protocols for investigating specific metabolic pathways in adipose (fat) tissue, skeletal muscle and the liver. This study is being done to improve methods of imaging and measuring molecules in a 3 Tesla or 7 Tesla scanners.

Conditions

  • Metabolism

Interventions

OTHER

3 Tesla

3 Tesla scanning with intravenous infusion of tracers

OTHER

7 Tesla

7 Tesla scanning with intravenous infusion of tracers

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of Texas Southwestern Medical Center

    collaborator OTHER

  • Duke University

    lead OTHER

Principal Investigators

  • Christopher Newgard, PhD · Duke University

  • Craig R. Malloy, MD · University of Texas Southwestern Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-10
Primary Completion
2017-05-17
Completion
2017-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01905722 on ClinicalTrials.gov